Edwards Lifesciences Corporatio found using ticker (EW) have now 21 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 128 and 73 with the average target price sitting at 93.14. Given that the stocks previous close was at 73.85 this would indicate that there is a potential upside of 26.1%. The 50 day moving average now sits at 78.81 and the 200 day MA is 96.43. The market cap for the company is $44,682m. Company Website: https://www.edwards.com
The potential market cap would be $56,353m based on the market concensus.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
